Digital Agentic AI: The shift from R&D to R&P will deliver the first... The next two years will be defined by a shift from R&D (Research & Development) to R&P (Research & Prediction), facilitated by agentic AI.
News FDA takes steps to limit non-human primate testing New draft guidance from the FDA says single-target antibodies will no longer need six-month toxicity testing in animals like macaques.
News Merck partners Valo on $3bn, AI-based Parkinson's project Merck has teamed up with Valo Health on a project to apply AI to the discovery of novel drug targets and drugs for Parkinson's.
News AI features in UK plan to reduce animal testing The UK government has set out an ambitious plan to phase out animal testing in scientific studies within five years.
News Specialty meds lift GSK's outlook in Walmsley's swan song Emma Walmsley's last set of financial results as GSK's chief executive has gone swimmingly, allowing the company to raise its 2025 forecasts.
News Merck looking to rare disease deals to build health momentum Germany's Merck KGaA is looking at making further acquisitions to boost its business, with a focus on life sciences and rare diseases.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.